[Characteristics of the treatment of ischemic heart disease with delayed-action verapamil].
Pre- and posttreatment indices of platelet and plasma hemostasis, parameters of long-term ECG-ST monitoring were measured in 30 coronary patients on long-term verapamil regimens. ++Anti-ischemic effect of the drug was dependent on clinical pattern of the disease and initial function of the platelets. Plasma hemostasis was found unaffected. Long-term verapamil treatment is indicated in stable angina pectoris class II and III provided platelets demonstrate enhanced functional activity.
Zharov
E I
EI
Styrova
T K
TK
Barinov
V G
VG
Martynov
A I
AI
Galichenko
I V
IV
Sedov
V P
VP
Vertkin
A L
AL
D000328:Adult; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D003692:Delayed-Action Preparations; D006403:Hematologic Tests; D006487:Hemostasis / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects / Q000502:physiology; D010975:Platelet Aggregation Inhibitors; D014700:Verapamil / Q000008:administration & dosage*
D003692:Delayed-Action Preparations; D010975:Platelet Aggregation Inhibitors; D014700:Verapamil
Osobennosti lecheniia bol'nykh ishemicheskoĭ bolezn'iu serdtsa prolongirovannym verapamilom.